Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceHBIO 53 3-Year RORE % is -1.06 as of Jun. 2026. GuruFocus rates HBIO with a GF Score™ of 53/100 and a GF Value™ of $12.30 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 785 Medical Devices & Instruments companies, Harvard Bioscience ranks better than 51.85% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Harvard Bioscience's 3-Year RORE % for the quarter that ended in Jun. 2026 was -1.06%.
The industry rank for Harvard Bioscience's 3-Year RORE % or its related term are showing as below:
HBIO's 3-Year RORE % is ranked better than 51.85% of 785
companies
in the Medical Devices & Instruments industry
Industry Median: -2.61
vs HBIO: -1.06
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Harvard Bioscience 3-Year RORE % Related Terms
Harvard Bioscience 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBIO vs MLSS, FEMY, POCI: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Harvard Bioscience (HBIO) has a 3-Year RORE % of -1.06 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Harvard Bioscience and its competitors. According to the industry distribution chart, Harvard Bioscience ranks #378 out of 785 companies in the Medical Devices & Instruments industry, placing it in the top 48.2%.
Is Harvard Bioscience's 3-Year RORE % too high?
Harvard Bioscience's current 3-Year RORE % is -1.06. Based on the distribution chart, Harvard Bioscience ranks #378 out of 785 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Harvard Bioscience has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's 3-Year RORE % compare to MLSS and FEMY?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #378 out of 785 companies for 3-Year RORE %. This puts Harvard Bioscience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current 3-Year RORE % is -1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Harvard Bioscience (HBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $12.30, compared to a current price of $8.06 — trading 34.5% below its estimated fair value. The current 3-Year RORE % is -1.06. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Harvard Bioscience (HBIO), the current 3-Year RORE % is -1.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (HBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of $8.06 is trading 34.5% below its estimated GF Value™ of $12.30.
GuruFocus considers Harvard Bioscience to be Possible Value Trap.
Key valuation signals for HBIO:
3-Year RORE %: -1.06
GF Value™: $12.30 vs. price of $8.06 (34.5% below fair value)
No single metric tells the full story. See the HBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for HBIO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBIO has been successfully added to your 
